

Compose

Inbox 4,862

Starred

Snoozed

Important

Sent

Drafts 112

Meet

New meeting

Join a meeting

Hangouts

Resti +

No recent chats
Start a new one



7 of 7 < >

Submission of Original Research titled "Capillary Lactate Level in Non-Severe and Severe Community-Acquired Pneumonia Patients"



Resti Yudhawati <restiyudhawati@gmail.com>
to editor.ijfmt

Oct 13, 2020, 10:58 PM ☆ ↶ ⋮

To,
The Editors
Indian Journal of Forensic Medicine and Toxicology

Dear Sir/Ma'am
We are submitting an Original Research titled "Capillary Lactate Level in Non-Severe and Severe Community-Acquired Pneumonia Patients" for consideration for publication in Indian Journal of Forensic Medicine and Toxicology.

I, Resti Yudhawati, as corresponding author certify that:

- * The manuscript is original work of all authors.
- * All authors made a significant contribution to this study.
- * This manuscript has not been submitted for publication and has not been published in any other journal.
- * All authors have read and approved the final version of the manuscript.

Thank you
Sincerely,

Resti Yudhawati
Department of Pulmonology and Respiratory Medicine
Faculty of Medicine
Airlangga University
restiyudhawati@gmail.com



Compose

- Inbox 4,862
- Starred
- Snoozed
- Important
- Sent
- Drafts 112

Meet

- New meeting
- Join a meeting

Hangouts

- Resti +



No recent chats
Start a new one



Indian Journal of Forensic Medicine & Toxicology <editor.ijfmt@gmail.com>
to me

Oct 13, 2020, 11:21 PM

Make all the tables properly closed
Write the designation for all the authors(researcher , scientist ,research scholar, professor,tutor,assistant/associate professor etc)
Quote references in text using superscript.

With warm regards
Yours sincerely

Prof R K Sharma
Editor, Indian Journal of Forensic Medicine & Toxicology
Former Head , Department of Forensic Medicine, A I I M S , New Delhi
<http://medicopublication.com/index.php/ijfmt/index>
www.ijfmt.com

Address for Correspondence

Dr R K Sharma
Editor, **IJFMT**
Institute of Medico-legal Publications
Logix Office Tower, Unit No. 1704, Logix City Centre Mall
Sector-32, Noida -201 301 (Uttar Pradesh)
<http://medicopublication.com/index.php/ijfmt/index>



1 **CAPILLARY LACTATE LEVEL IN NON-SEVERE AND SEVERE COMMUNITY-**
2 **ACQUIRED PNEUMONIA PATIENTS**

3 Running Head: Pneumonia and Capillary Lactate Level
4

5 Resti Yudhawati¹, Kowiy Akbar²
6

7 *¹Assistant Professor, ²Senior Resident, Department of Pulmonology and Respiratory Medicine,*
8 *Faculty of Medicine, Airlangga University – Soetomo General Hospital, Surabaya - Indonesia*
9

10
11
12
13
14
15
16
17
18
19
20
21
22 **Corresponding Author** : Resti Yudhawati

23 Departement of Pulmonology and Respiratory Medicine, Faculty of Medicine, Dr. Soetomo
24 Teaching Hospital, Universitas Airlangga

25 Jalan Mayjen Prof. Dr. Moestopo 6-8, Surabaya, Indonesia

26 Phone : +6231 5501656

27 E-mail : restiyudhawati@gmail.com
28
29
30
31
32
33

34 **ABSTRACT**

35 **Background:** Community-acquired pneumonia is an inflammatory disease of the lung caused by
36 microorganisms acquired from a non-hospital environment. The pneumonia severity index and
37 ATS/IDSA severity criteria are widely used to predict the severity of CAP. Lactate is a biomarker
38 that can be measured by point-of-care devices that provide results in a short of time. This study
39 aimed to determine the difference in capillary lactate level between non-severe and severe
40 pneumonia to provide an additional method to quickly stratify pneumonia severity and treat it
41 accordingly.

42 **Methods:** This cross-sectional study was performed in the emergency room of a regional research
43 hospital. The pneumonia diagnosis was determined by the symptoms, physical examination and
44 radiological findings. Capillary lactate level was measured with Accutrend Plus lactate point-of
45 care device. Severity stratification was done according to ATS/IDSA criteria. The mean of lactate
46 level in all subjects was 3.40 ± 1.52 , in non-severe pneumonia subgroup was 2.25 ± 0.94 , and
47 4.56 ± 1.01 in severe pneumonia subgroup. Lactate is significantly higher in severe pneumonia
48 subgroup. The cut-off point of lactate level for severity group was 3.2 mmol/L (95.5% sensitivity,
49 86.4% specificity).

50 **Conclusion:** The early prediction of CAP severity is essential to determine the need for admission
51 in the intensive care unit and close follow up. The lactate level can be used for immediate severity
52 stratification in emergency departments.

53 **Keywords:** lactate; pneumonia; pneumonia severity index

54

55

56

57

58

59

60

61

62

63 **INTRODUCTION**

64 Pneumonia is one of the most common infectious disease causing significant morbidity
65 and mortality, either in developed or developing countries.¹ Its clinical signs are new or
66 progressive infiltrates on chest radiography accompanied by certain symptoms such as cough,
67 sputum production, fever, and shortness of breath.^{1,2}

68 It is imperative to give antibiotic therapy as early as possible after bacterial pneumonia
69 diagnosis is confirmed to reduce mortality rate.^{2,3} Several scoring systems are available to assess
70 pneumonia severity in emergency department, which mostly consist of several clinical sign
71 examination and biomarker measurement.^{2,4-7} According to pneumonia severity and close
72 monitoring of clinical response, an appropriate empirical antibiotic determination is crucial to
73 ensure successful management of pneumonia.⁸ However, those scoring systems have weakness of
74 requiring venous blood samples, which needs particular expertise, cost, and delayed results.⁹

75 One of the most frequently utilized biomarkers in infection cases is lactate, which is already
76 used in sepsis management guidelines. Several studies showed that lactate measurement had
77 clinical utility in initial evaluation and management of pneumonia.¹⁰⁻¹⁷ Several point-of-care
78 devices are available for lactate measurement, which only need microliters of blood. Compared to
79 arterial sampling, capillary sampling is easier to perform, less painful, cheaper, confer faster
80 results, and able to decrease the chance of needle stick injury to health workers.¹⁸ Capillary lactate
81 measurement can be done quickly in busy emergency departments to triage patients according to
82 their severity.¹¹

83 Capillary lactate as severity biomarker in pneumonia is yet to be a routine examination to
84 date. This study aimed to analyze the comparison of capillary lactate between severe and non-
85 severe community-acquired pneumonia patients.

86

87 **METHODS**

88 **Subjects**

89 The population of this study was Community-Acquired Pneumonia (CAP) patients
90 admitted into the emergency department of Soetomo General Hospital. Eligible subjects were
91 selected by consecutive sampling method. The inclusion criteria were patients with CAP, over 21
92 years of age, and willingly participating in the study. The exclusion criteria was patients who had
93 concomitant infection source outside of the lung.

94 CAP was defined as an inflammation of the lung caused by infectious agents, acquired
95 outside healthcare system, in the patients who had no history of admission in the last 90 days,
96 while having new or progressive infiltrate in chest radiology examination accompanied by
97 supporting clinical symptoms and signs. Pneumonia Severity Index (PSI) was classified according
98 to American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) criteria. Severe
99 pneumonia was defined in patients who had one major criterion or three minor criteria at minimum.
100 The capillary lactate level was measured with Accutrend Plus™ portable lactate device when the
101 patients still in the emergency department.

102

103 **Ethical clearance**

104 This study follows the principles of the Helsinki declaration. Research ethics has been
105 issued by Dr. Soetomo Hospital Surabaya Ethics Committee (Ethical Clearance Number
106 684/Panke.KKE/XII/2016) before the start of the study.

107

108 **Statistical Analysis**

109 The result was analyzed with statistical software package using appropriate statistical
110 significance testing. All data were expressed as means \pm SD. Statistical analysis was performed
111 using statistical SPSS software package for Windows, version 17.0 (SPSS, Inc., Chicago, IL). The
112 comparison of capillary lactate level was analyzed using Independent T-Test for normally
113 distributed interval variables and Mann–Whitney U test for abnormally distributed interval
114 variables.

115

116 **RESULTS**

117 **Characteristic of Pneumonia Severity Index in CAP Patients**

118 It was found that 22 patients was experienced non-severe pneumonia and the other 22
119 patients had severe pneumonia. Major criteria in severe pneumonia that mostly found was
120 mechanic ventilation utilization with 15 patients (68%), while the minor criteria was respiratory
121 rate ≥ 30 x/min with 19 patients (86%), and PaO₂/FiO₂ ≤ 250 also with 19 patients (86%) (Table
122 1).

123 **Table 1.** Characteristic of Pneumonia Severity Index in CAP Patient

Characteristics	Severe Pneumonia (n=22)	Non-severe Pneumonia (n=22)
Major criteria		
Mechanic ventilation	15 (68%)	0
Vasopressor	7 (32 %)	0
Minor criteria		
Respiratory rate ≥ 30 x/min	19 (86%)	4 (18%)
$P_aO_2/FiO_2 \leq 250$	19 (86%)	2 (9%)
Multilobar infiltrates	10 (45%)	0
Disorientation	6 (27%)	0
BUN ≥ 20 mg/dl	13 (59%)	7 (32%)
White blood count < 4.000 sel/mm ³	1 (5%)	0
Platelets < 100.000 sel/mm ³	1 (5%)	0
Temperature $< 36^\circ C$	0	0
Hipotension (Systolic < 90 mmHg)	7 (32%)	0

124

125 **The difference of lactate level based on major or minor criteria found in severe pneumonia**
126 **group**

127 There were no significant difference shown in severe pneumonia group which marked by
128 the use of only ventilator; only vasopressor; ventilator combined with vasopressor; and only minor
129 criteria. Therefore, it can be concluded that there was no specific severe pneumonia criteria that
130 affect lactate level dominantly in severe pneumonia (Table 2).

131 **Table 2.** The Difference of Lactate Level Based on Major or Minor Criteria Found in Severe
132 Pneumonia Group

Group	Frequency	Mean of lactate level	p-Value (Kruskal Wallis test)
Only ventilator	9	4.54 \pm 0.67	0.813
Only vasopressor	1	4.0	
Ventilator + vasopressor	6	4.73 \pm 1.30	
Only minor criteria	6	4.5 \pm 1.34	

133

134 **Characteristic of Comorbidities Disease in CAP Patients between Severe Pneumonia Group**
135 **and Non-severe Pneumonia Group**

136 The comorbidities disease was mostly lung tuberculosis, both in severe pneumonia and
137 non-severe pneumonia groups. The correlation between comorbidities and PSI was $p > 0.05$, hence
138 it can be concluded that there was no significant correlation between comorbidities disease and
139 pneumonia severity index (Table 3)

140 **Table 3.** Characteristic of Comorbidities Disease in CAP Patients

Comorbidities	Frequency in Severe Pneumonia	Frequency in Non-severe Pneumonia	p-Value (Fischer exact test)
Tuberculosis	9 (40.9%)	11 (50%)	0.762
Diabetes Mellitus	6 (27.3%)	2 (9.1%)	0.240
Malignancy	4 (18.2%)	5 (22.7%)	1.000
Heart failure	0	2 (9.1%)	0.488
Asthma	0	1 (4.5%)	1.000

141

142 **The Comparison of Capillary Lactate Level in Comorbidities Disease**

143 The comparison of lactate level in the subjects both with and without comorbidities disease,
 144 showed no significant difference with p-value >0.05 (Table 4).

145 **Table 4.** The Comparison of Capillary Lactate Level in Comorbidities Disease

Comorbidities Disease	Pneumonia Severity Index	Mean of Lactate on Subject with Comorbidities	Mean of Lactate on Subject without Comorbidities	p-Value
Tuberculosis	Severe	4.644 ± 1.1458	4.500 ± 0.9531	0.751
	Non-severe	2.309 ± 0.9894	2.182 ± 0.9239	0.758
Diabetes Mellitus	Severe	4.967 ± 0.6653	4.406 ± 1.0933	0.257
	Non-severe	2.900 ± 1.2728	2.180 ± 0.9134	0.312
Malignancy	Severe	4.675 ± 1.6460	4.533 ± 0.8852	0.538
	Non-severe	2.480 ± 0.9066	2.176 ± 0.9608	0.537
Heart failure	Severe	---	---	
	Non-severe	3.100 ± 1.8385	2.160 ± 0.8407	0.364
Asthma	Severe	---	---	
	Non-severe	3.2	2.2 ± 0.9343	0.364

146

147 **Capillary Lactate Level in CAP Patients**

148 The mean of capillary lactate level in community pneumonia patients was higher in severe
 149 pneumonia group than in non-severe pneumonia group. Furthermore, the lactate level in severe
 150 pneumonia group had a wider range of value and a bigger variations than in non-severe pneumonia
 151 group (Table 5).


152 **Table 5.** Capillary Lactate Level in CAP Patients

Group	Mean	Minimum	Maximum
All subjects	3.40 ± 1.516	1.1	7.1
Severe pneumonia	4.56 ± 1.012	2.1	7.1
Non-severe pneumonia	2.25 ± 0.936	1.1	4.4

153

154 **The Comparison of Capillary Lactate Level in CAP Patients between Severe Pneumonia**
155 **Group and Non-severe Pneumonia Group**

156 The normality test of capillary lactate level in CAP patients was conducted using
157 Kolmogorov Smirnov test, and the result was the capillary lactate level normally distributed with
158 $p > 0.05$. Therefore, to investigate the hypothesis whether any difference of capillary lactate level
159 between severe pneumonia group and non-severe pneumonia group was using Independent Sample
160 T-Test, and the result presented a significant difference with $p < 0.001$. The cut-off point of
161 capillary lactate level with the most optimal AUC, and the highest sensitivity and specificity, to
162 differentiate severe and non-severe pneumonia was found in lactate level of 3.2 mmol/L with AUC
163 of 0.946, sensitivity of 95.5%, and specificity of 86.4% (Figure 1).



164

165 **Figure 1.** The curve of ROC and dot diagram to determine cut-off point of lactate level

166 Further analysis was using Cohen's kappa coefficient inter-rater agreement, and the score
167 obtained of Cohen's kappa coefficient was 0.773. It showed that there was a good suitability
168 between the distribution of subjects based on lactate level compared to distribution based on
169 IDSA/ATS criteria to determine pneumonia severity index, which according to Fleiss Cohen's
170 kappa coefficient > 0.75 is used to show a good suitability (Table 6).

171 **Table 6.** The suitability of lactate level with IDSA/ATS

	Severe Pneumonia	Non-severe Pneumonia	Cohen's kappa coefficient
High Lactate ($\geq 3,2$ mmol/L)	21 cases	4 cases	0.773 (95% CI 0,587 – 0,959)
Low Lactate ($< 3,2$ mmol/L)	1 cases	18 cases	

172

173 **DISCUSSION**

174 In this study, the subjects were distributed into severe pneumonia and non-severe
175 pneumonia group, which was determined based on major and minor criteria of severe pneumonia
176 according to IDSA/ATS. According to the latest ATS guideline for pneumonia, it was mentioned
177 that there are two major criteria and nine minor criteria.

178 The results presented that the most comorbidities disease was lung tuberculosis, followed
179 by diabetes mellitus, malignancy, and heart failure. Statistical analysis in order to investigate the
180 correlation between comorbidities disease and pneumonia severity index resulted a value of p
181 >0.05 . Therefore, it can be concluded that there was no significant correlation between
182 comorbidities disease and PSI in this study. This result proved that despite the comorbidities
183 disease is potentially affect blood lactate level, its insignificant difference of number between
184 severe pneumonia and non-severe pneumonia group could resolve the bias of the cause of the
185 increase in lactate from those comorbidities disease. In line with the study by Demirel, that
186 reported no significant correlation between comorbidities disease and pneumonia severity index
187 in their research.¹⁹

188 The result of this study showed the mean of capillary lactate level in subjects was $3.40 \pm$
189 1.516 mmol/L, with the mean of capillary lactate level in severe pneumonia group was $4.56 \pm$
190 1.012 mmol/L, and 2.25 ± 0.936 in non-severe pneumonia group. This statistical analysis
191 calculation proved that there was a significant difference between both of the groups with $p < 0.001$.
192 The study conducted by Demirel, also found a significant difference between lactate level in died
193 patients and survived patients ($p < 0.001$), with the mean of lactate level in pneumonia was $3.53 \pm$
194 3.59 mmol/L, in died patients was 7.76 ± 5.81 mmol/L, and 2.35 ± 0.99 mmol/L in survived
195 patients.¹⁹

196 Furthermore, ROC analysis was used to observe the highest cut-off point, sensitivity, and
197 specificity. The highest cut-off point was 3.2 mmol/L with AUC of 0.946 , sensitivity of 95.5% ,
198 and specificity of 86.4% . Similarly, Demirel found the highest cut-off point was 3.35 mmol/L,
199 AUC of 0.929 , sensitivity of 86.4% , and specificity of 88.6% .¹⁹ The cut-off point obtained by this
200 study can be used to help differentiate community-acquired pneumonia patients into severe and
201 non-severe groups and assist in their proper management.

202 The immune response in pneumonia causes pulmonary ventilation and hemodynamic
203 derangement which result in the decrease of systemic oxygen delivery. Besides, there is also the

204 increase of metabolism causing higher systemic oxygen consumption. The imbalance between the
205 reduction of oxygen delivery and increase of oxygen consumption will increase the systemic
206 oxygen extraction ratio and reduce oxygen saturation. The increase of systemic oxygen extraction
207 ratio above certain tolerance level (50 – 60%) will trigger anaerobic metabolism, which causes
208 higher lactate production. Therefore, lactate concentration is inversely related to systemic oxygen
209 delivery and oxygen saturation and has the ability to reflect pneumonia severity level.²⁰

210 CAP patients in the emergency department are usually in the early phase of hemodynamic
211 disorder, characterized by significantly increased lactate level, but still normal vital signs due to
212 adaptation response of catecholamine release that prevents shock to occur. This condition is
213 called "occult shock", which can progress to sudden cardiopulmonary collapse. Therefore, lactate
214 measurement is essential as an early warning marker for detecting that condition.²⁰

215 There are several limitations in this study. First, most of the subject was already treated in
216 prior hospital before being referred, raising the potential bias from the treatment given before the
217 lactate level is measured. Secondly, the diagnostic criteria to differentiate the subject into severe
218 and non-severe group was ATS/IDSA criteria, which has two major and nine minor criteria. Each
219 of them has different underlying pathophysiology that potentially had different effects on lactate
220 level.

221

222 **CONCLUSION**

223 This study showed that capillary lactate level had the ability to differentiate CAP patients
224 into severe and non-severe group. The optimal cut-off point for the differentiation is 3.2 mmol/L.
225 Early severity prediction of community-acquired pneumonia is important to decide the effective
226 treatment for patients in the intensive care unit and closer monitoring. Capillary lactate level can
227 be used for quick classification of pneumonia patients in emergency departments.

228

229 **CONFLICT OF INTEREST**

230 The authors confirm that this article content has no conflict of interest.

231

232 **ACKNOWLEDGEMENTS**

233 We truly thank the patients who participated in this study and the authorities and staff of Dr.
234 Soetomo Hospital, Surabaya, Indonesia, who helped and supported us during the study.

235

236 **FUNDING**

237 This research did not receive any specific grant from funding agencies in the public, commercial,
238 or not-for-profit sectors.

239

240 **AUTHOR'S CONTRIBUTION**

241 RY and KA designed the study, collected samples, gathered data, analyzed the data, made tables
242 and figures, wrote the manuscript, and contributed to review and revise. All authors have been
243 approved the final version.

244

245 **REFERENCES**

- 246 1. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-
247 Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *The New England*
248 *Journal of Medicine* 2015; **373**(5):415-27
- 249 2. Mandell LA, Wunderik RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et.al. Infectious
250 Diseases Society of America/ American Thoracic Society Consensus Guidelines on The
251 Management of Community Acquired Pneumonia in Adults. *Clinical Infectious Diseases*
252 2007; **44**:S27-72
- 253 3. Musher DM, Thorner AR. Community-acquired pneumonia. *The New England Journal of*
254 *Medicine* 2014; **371**(17): 1619-28.
- 255 4. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al. Prospective
256 comparisons of three validated prediction rules for prognosis in community-acquired
257 pneumonia. *The American Journal of Medicine* 2005; **118**:384-92.
- 258 5. Fine. Pneumonia severity index. *The New England Journal of Medicine*. 1997; **336**:243-50.
- 259 6. Lim WS, Eerden MMVD, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining
260 community acquired pneumonia severity on presentation to hospital an international
261 derivation and validation study. *Thorax* 2003; **58**:377-82.
- 262 7. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune IL, et al. British thoracic
263 society guidelines for the management community acquired pneumonia in adult update 2009.
264 *Thorax* 2009; **64**:155.
- 265 8. American Thoracic Society. Guidelines for the Management of Adults with Community-

- 266 acquired Pneumonia: Diagnosis, Assessment of Severity, Antimicrobial Therapy, and
267 Prevention. *American Journal of Respiratory and Critical Care Medicine* 2001; **163**:pp.
268 1730–1754.
- 269 9. Crain MC, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic
270 prescription, prognostic markers and mediators. *European Respiratory Journal* 2007;
271 **30**:556–573
- 272 10. Chalmers JD, Singanayagam A, Akram A, Mandal P, Choudhury G, Smith M, et al. Lactate
273 is an independent marker of severity in hospitalised patients with community-acquired
274 pneumonia. *European Respiratory Journal* 2011; **38**(Suppl 55):p1463.
- 275 11. Chen Y, Li C. Lactate on emergency department arrival as a predictor of mortality and site-
276 of-care in pneumonia patients: a cohort study. *Thorax* 2015; **70**(5):404-410.
- 277 12. Gwak M, Jo S, Jeong T, Lee J, Jin Y, Yoon J, et al. Initial serum lactate level is associated
278 with inpatient mortality in patients with community-acquired pneumonia. *The American*
279 *Journal of Emergency Medicine* 2015; **33**(5):685-690.
- 280 13. Jo S, Jeong T, Lee J, Jin Y, Yoon J, Park B, et al. Validation of modified early warning score
281 using serum lactate level in community-acquired pneumonia patients. The National Early
282 Warning Score–Lactate score. *The American Journal of Emergency Medicine* 2016;
283 **34**(3):536-541.
- 284 14. Liu W, Peng L, Hua S. Clinical significance of dynamic monitoring of blood lactic acid,
285 oxygenation index and C-reactive protein levels in patients with severe pneumonia.
286 *Experimental and Therapeutic Medicine* 2015; **10**(5):1824-1828.
- 287 15. Mohamed K, Ahmed D. Prognostic value of lactate clearance in severe community acquired
288 pneumonia. *Egyptian Journal of Chest Diseases and Tuberculosis* 2014; **63**(4):1053-1058.
- 289 16. Ose D, Berzins A, Grigorovica K, Klucniks A, Sabelnikovs O. Lactate as a Predictor in Severe
290 Pneumonia. *Acta Chirurgica Latviensis* 2015; **15**(1):29-34.
- 291 17. Sahal A, Das J. Does a relationship exist between serum albumin and lactate with the length
292 of stay in patients admitted with community acquired pneumonia?. *Thorax* 2013; **68**(Suppl 3):
293 A185.3-A186.
- 294 18. Gaieski DF, Drumheller BC, Goyal M, Fuchs BD, Shofer FS & Zogby K. Accuracy of
295 Handheld Point-of-Care Fingertip Lactate Measurement in the Emergency Department.
296 *Western Journal of Emergency Medicine* 2011; **14**:p.58-62.

- 297 19. Demirel B. Lactate levels and pneumonia severity index are good predictors of in-hospital
298 mortality in pneumonia. *The Clinical Respiratory Journal* 2018; **12**(3):991-995.
- 299 20. Chalmers J, Pletz M, Aliberti S. Community-acquired pneumonia. European R. James D,
300 Chalmers M, Pletz S, editors. 2014.



Resti Yudhawati <restiyudhawati@gmail.com>

Submission of Original Research titled "Capillary Lactate Level in Non-Severe and Severe Community-Acquired Pneumonia Patients"

Indian Journal of Forensic Medicine & Toxicology <editor.ijfnt@gmail.com>
To: Resti Yudhawati <restiyudhawati@gmail.com>

Thu, Oct 15, 2020 at 11:34 PM

I have the pleasure to inform you that your paper has been accepted for publication.
Pay 200 US\$ as manuscript handling charges.

You can make the payment by only this
Bank details for NEFT

Name of account	Institute of Medico-Legal Publications Pvt Ltd
Bank	HDFC Bank
Branch	Sector-50, Noida-201 301
Account number	09307630000146
Type of Account	Current Account
MICR Code	110240113
RTGS/NEFT/IFSC code	HDFC0000728
Swift Code	HDFCINBBDEL

Please quote reference number. Email us the proof of deposit.(scan copy or photograph of the slip of bank transfer)

Your acceptance letter would be sent after receipt of charges.

After this no further amendment will be entertained in the manuscript

Note for authors - Please note that your submission is final and no further amendments would be accepted in manuscript after issue of acceptance letter. You are hereby advised again to check manuscript. Re submit file if corrections are there. New acceptance letter would not be issued to change in authors sequence or affiliation

With warm regards
Yours sincerely

Prof R K Sharma
Editor, Indian Journal of Forensic Medicine & Toxicology
Former Head , Department of Forensic Medicine, A I I M S , New Delhi
<http://medicopublication.com/index.php/ijfnt/index>
www.ijfnt.com

Address for Correspondence

Dr R K Sharma
Editor, IJFMT
Institute of Medico-legal Publications
Logix Office Tower, Unit No. 1704, Logix City Centre Mall
Sector- 32, Noida - 201 301 (Uttar Pradesh)

<http://medicopublication.com/index.php/ijfnt/index>

[Quoted text hidden]



Resti Yudhawati <restiyudhawati@gmail.com>

Pre-release copy of IJFMT April-June 2021

Indian Journal of Forensic Medicine & Toxicology <editor.ijfmt@gmail.com>

Wed, Mar 3, 2021 at 1:08 AM

Bcc: restiyudhawati@gmail.com

PFA

I am enclosing Pre-release copy of IJFMT April-June 2021 , Please check your article carefully. Report any errors. Please do not try to update your article. Just look for errors. Reply within 4 days of this email.

Mention the title of the article for the correction along with the page number, correction without the mention of the title of the article and page number won't be entertained, preferably highlight the corrections with the pdf.

No amendments can be submitted to change affiliation of author/s. only ERRORS would be corrected. No changes in text are allowed except ERRORS of formatting.

 [IJFMT_April-June 2021_IJFMT.pdf](#)

With warm regards
Yours sincerely

Prof R K Sharma
Editor, Indian Journal of Forensic Medicine & Toxicology
Former Head , Department of Forensic Medicine, A I I M S , New Delhi
<http://medicopublication.com/index.php/ijfmt/index>
www.ijfmt.com

Address for Correspondence

Dr R K Sharma
Editor, IJFMT
Institute of Medico-legal Publications
Logix Office Tower, Unit No. 1704, Logix City Centre Mall
Sector- 32, Noida - 201 301 (Uttar Pradesh)

<http://medicopublication.com/index.php/ijfmt/index>



Resti Yudhawati <restiyudhawati@gmail.com>

Pre-release copy of IJFMT April-June 2021

Resti Yudhawati <restiyudhawati@gmail.com>

Wed, Mar 3, 2021 at 8:40 PM

To: Indian Journal of Forensic Medicine & Toxicology <editor.ijfmt@gmail.com>

Dear Editor,

Thank you for the notification. We would apply for amendments for our articles:

1. Title: Viral Profile and Clinical Characteristic in Acute Asthma Exacerbation Patients:

a. page 3305, where is the detail of the corresponding author? Please kindly provide it (Corresponding Author : Resti Yudhawati

Departement of Pulmonology and Respiratory Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Airlangga University

Jalan Mayjen Prof. Dr. Moestopo 6-8, Surabaya, Indonesia

Phone : +6231 5501656

E-mail : restiyudhawati@gmail.com)

b. page 3307, please bold the sentence of "Characteristic of Asthma Exacerbation's Trigger" because that is the title for paragraph below (already highlighted in yellow)

c. page 3309, please bold the sentence of "Subject Characteristics Based on Triggers of Asthma Exacerbation" because that is the title for paragraph below (already highlighted in yellow)

2. Title: Capillary Lactate Level in Non-Severe and Severe Community-

Acquired Pneumonia Patients, page 3313, we think all is clear, we do not have any revision requests, thank you for your hard work

We are really thank you for accepting our articles, hopefully all the issues will resolve soon as well as the publication. Thank you in advance for your consideration.

Best regards,
Resti Yudhawati

[Quoted text hidden]



Resti Yudhawati <restiyudhawati@gmail.com>

Submission of Original Research titled "Capillary Lactate Level in Non-Severe and Severe Community-Acquired Pneumonia Patients"

Indian Journal of Forensic Medicine & Toxicology <editor.ijfmt@gmail.com>

Mon, Oct 19, 2020 at 12:39 AM

To: Resti Yudhawati <restiyudhawati@gmail.com>

Find enclose soft copy of acceptance letter as attachment.

With warm regards

Yours sincerely

Prof R K Sharma
Editor, Indian Journal of Forensic Medicine & Toxicology
Former Head , Department of Forensic Medicine, A I I M S , New Delhi
<http://medicopublication.com/index.php/ijfmt/index>
www.ijfmt.com

Address for Correspondence

Dr R K Sharma
Editor, IJFMT
Institute of Medico-legal Publications
Logix Office Tower, Unit No. 1704, Logix City Centre Mall
Sector- 32, Noida - 201 301 (Uttar Pradesh)

<http://medicopublication.com/index.php/ijfmt/index>

[Quoted text hidden]

**Resti Yudhawati_16 Oct 2020.pdf**

161K